Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 88 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Epilepsy (Treatment Refractory) Clear all
Recruiting Phase 2 Interventional

Treatment of Refractory Infantile Spasms With Fenfluramine

NCT04289467
View directory record Official record
Conditions
Infantile Spasm
Interventions
Fenfluramine
Drug
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
12 Months to 36 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 3 Interventional

Atkins Plus KetoCal for Childhood Epilepsy

NCT00681239
View directory record Official record
Conditions
Epilepsy
Interventions
Modified Atkins diet and KetoCal
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 31, 2009 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Phase 1 Interventional

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

NCT06700811
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
Interventions
Ketogenic diet
Drug
Lead sponsor
Heather Olson
Other
Eligibility
0 Days to 9 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Not applicable Interventional

Diagnosing Epilepsy To EffeCT Change

NCT07110337
View directory record Official record
Conditions
Epilepsy, Epilepsy (Treatment Refractory)
Interventions
Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)
Device
Lead sponsor
Epiminder America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Phase 4 Interventional

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

NCT05684978
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Perampanel
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Not applicable Interventional

Ketogenic Diet for Refractory Status Epilepticus

NCT01796574
View directory record Official record
Conditions
Status Epilepticus, Seizure, Epilepsy, Refractory Status Epilepticus, Medically Resistant Status Epilepticus
Interventions
Ketogenic diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Phoenix, Arizona • Honolulu, Hawaii • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

NCT02551731
View directory record Official record
Conditions
Spasms, Infantile
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
6 Months to 36 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Withdrawn Phase 3 Interventional

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

NCT02726867
View directory record Official record
Conditions
Epilepsy, Status Epilepticus
Interventions
levetiracetam, lacosamide, Ketamine, Phenobarbital
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

NCT00368472
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

NCT00228969
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
RWJ-333369
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Not applicable Interventional

Exercise as Adjunctive Treatment for Refractory Epilepsy

NCT04607317
View directory record Official record
Conditions
Refractory Epilepsy, Epilepsy
Interventions
Exercise program, Health Coach, Health Information
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

NCT03865732
View directory record Official record
Conditions
PCDH19-Related Epilepsy
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Not applicable Interventional

The Potential of a Low Glutamate Diet as a Treatment for Pediatric Epilepsy

NCT04545346
View directory record Official record
Conditions
Epilepsy in Children, Epilepsy in Youth, Randomized Controlled Trial, Refractory Epilepsy, Diet Intervention
Interventions
Low Glutamate diet
Other
Lead sponsor
American University
Other
Eligibility
2 Years to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 4, 2026, 1:24 PM EDT
Withdrawn Not applicable Interventional

The Utility of NIOM During LITT for Refractory MTLE

NCT02913742
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
monitoring by depth electrode
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

NCT01278173
View directory record Official record
Conditions
Adult Refractory Complex Partial Seizures
Interventions
Sabril
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
22
States / cities
San Francisco, California • New Haven, Connecticut • Dover, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 4, 2026, 1:24 PM EDT
Available No phase listed Expanded access

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

NCT04457687
View directory record Official record
Conditions
Epilepsies, Myoclonic, Drug Resistant Epilepsy
Interventions
Lorcaserin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

NCT05218655
View directory record Official record
Conditions
Inherited Mitochondrial Disease
Interventions
Vatiquinone
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Not listed
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
La Jolla, California • Stanford, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional

High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy

NCT02264652
View directory record Official record
Conditions
Epilepsy
Interventions
HD Transcranial Direct Stimulation
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
9 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

NCT00152503
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Seletracetam (UCB44212)
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • St. Petersburg, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Not applicable Interventional

Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application

NCT06425029
View directory record Official record
Conditions
Epilepsy, Refractory Epilepsy, Music
Interventions
Experimental Intervention (Music A), Active Comparator Intervention (Music B), Active Comparator Intervention (Music C)
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Worcester, Massachusetts • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy

NCT01906398
View directory record Official record
Conditions
Epilepsy
Interventions
ketogenic diet
Other
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Not listed Not applicable Interventional

Decreasing Parental Stress of Caregivers of Infants With Infantile Spasms by Using Telemedicine Technology

NCT04086992
View directory record Official record
Conditions
Infantile Spasms, Non-Intractable
Interventions
Remote monitoring
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 30 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

NCT05019885
View directory record Official record
Conditions
Drug Resistant Epilepsy, Medically Refractory Epilepsy, Refractory Epilepsy
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Madeline Fields
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 3 Interventional

Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures

NCT00113815
View directory record Official record
Conditions
Partial Seizure Disorder, Epilepsy, Seizures
Interventions
topiramate, placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 24 Months
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 4, 2026, 1:24 PM EDT